ArticleInternational journal of clinical oncology2026
Observed ALK fusion/rearrangement frequency across comprehensive genomic profiling platforms in Japanese routine oncology practice.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinically relevant ALK alterations are identified across routine comprehensive genomic profiling (CGP), but their observed frequency may vary according to testing context. Because ALK-directed treatment is primarily linked to fusion/rearrangement events, we sought to define a nationwide benchmark for interpreting ALK fusion/rearrangement findings across routine CGP settings in Japan.
methodsWe performed a retrospective descriptive analysis of anonymized aggregated Center for Cancer Genomics and Advanced Therapeutics data through March 31, 2025. Case-level observed frequencies within the CGP-tested cohort were evaluated across 97,343 cases, five CGP assays, 12 organ groups, and pooled tissue-based versus liquid-based settings. A supplementary fusion-only sensitivity analysis evaluated definitional dependence.
resultsThe overall case-level observed ALK fusion/rearrangement frequency within the CGP-tested cohort was 0.329% (320/97,343; 95% CI 0.294-0.367). Observed frequencies ranged from 0.152% for NCC Oncopanel to 0.598% for FoundationOne Liquid CDx (P < 0.001). When pooled by specimen context, observed frequency was 0.280% in tissue-based CGP and 0.561% in liquid-based CGP (P < 0.001). Thoracic tumors showed the highest observed frequency (1.988%), whereas liver tumors showed no positive cases. In the fusion-only sensitivity analysis, the overall frequency decreased to 0.234%, with a larger reduction in pooled liquid-based CGP than in pooled tissue-based CGP, reflecting reporting-category and context dependence rather than lower analytical sensitivity, while the broad directional pattern was preserved.
conclusionThis nationwide C-CAT analysis provides an implementation-oriented CGP-cohort benchmark for panel-aware and specimen-context-aware interpretation of observed ALK findings; these case-level frequencies should not be interpreted as population prevalence.
Indexed as
Identifiers
42509446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.